ALL GIMEMA 0904(Active): Treatment of high-risk ALL and MRD-monitoring
ALL GRAALL 02/2005(Active): HyperC vs. standard induction and late intensification in Ph neg. ALL
ALL NILG 09/00(Active): Postremission programme according to MRD
ALL PALG 5-2007 MRD(Active): Optimization of the therapy of adult acute lymphoblastic leukemia according to risk factors and monitoring of minimal residual disease
ALL GRAALLPHAG06/ EWALL-PH-01(Active): Effectiveness and compatibility of a combination therapy of Dasatinib (trade name: Sprycel®) with Vincristin and Dexamethason with Philadelphia chromosome positive ALL
ALL GRAAPH 02/2005(Active): Imatinib-based vs. standard imatinib containing Hyper CVAD induction in de novo Ph+ ALL
ALL NILG 09/00/Ph+(Active): Intermittent Imatinib programme in Ph+ ALL and CML blast crisis
Mature B-ALL/NHL
de novo/non-treated
ALL GMALL B-ALL/NHL 2002(Active): Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults
CML Homoharringtonine(Active): Homoharringtonine in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
de novo/non-treated
CML Imatinib+Zoledronic Acid(Active): Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
Chronic Phase
Imatinib resistance, -intolerance
CML SKI606(Active): Study Evaluating SKI-606 in Philadelphia Chromosome Positive Leukemias
de novo/non-treated
CML Bosutinib Versus Imatinib(Active): Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
CML Dasatinib Vs. Imatinib 400 mg(Active): A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
CML STI571 Spirit(Active): High-dose of Imatinib (STI571) vs. low-dose Imatinib in combination with cytostatics vs. reference-dose of Imatinib (SPIRIT-study)
CML IV(Active): Imatinib vs. Imatinib+Interferon or Imatinib 800mg and SCT in CML
Lymphatic blast crisis
de novo/non-treated
ALL NILG 09/00/Ph+(Active): Intermittent Imatinib programme in Ph+ ALL and CML blast crisis
AMLCG-2000(Active): Biology and therapystrategy of AML an its subgroups
MDS 5-Azacitidine(Active): Subcutaneous Azacitidine + best supportive care vs. conventional regimens + best supportive care
MDS 5-Azacytidine II(Active): Study of maintenance of response with azacytidine administered subcutaneously for 5 consecutive days every 28 daysfor 24 months in adult subjects with Myelodysplastic syndromes (MDS) in response after intensive chemotherapy
MDS AMG531(Active): AMG531 in low- or intermediate-1 risk MDS with Thrombopenia
